NEW YORK, May 22, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=149537&from=4CLAS ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of West Pharmaceutical Services, Inc. regarding a class action lawsuit due to alleged misleading statements and operational inefficiencies that negatively impacted the company's financial performance during the specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from February 16, 2023, to February 12, 2025 [3]. - Allegations include: - The company claimed strong visibility into customer demand while actually facing significant destocking in its high-margin HVP portfolio [3]. - The SmartDose device, marketed as a high-margin growth product, was found to be dilutive to profit margins due to operational inefficiencies [3]. - Margin pressures raised the risk of costly restructuring, including exiting continuous glucose monitoring contracts with long-term customers [3]. - Positive statements made by the defendants regarding the company's business and prospects were materially false or misleading [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by July 7, 2025, to participate in potential recovery [4]. - Registration includes enrollment in a portfolio monitoring software for status updates throughout the case lifecycle [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [5]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that inflated the company's stock [5].

BENSALEM, Pa., May 20, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against West Pharmaceutical Services, Inc. ("West" or the "Company") (NYSE: WST).IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN WEST PHARMACEUTICAL SERVICES, INC. (WST), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE JULY 7, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Cont ...

Core Viewpoint - A class action lawsuit has been filed against West Pharmaceutical Services, Inc. for alleged misleading statements and failure to disclose significant operational issues during the Class Period from February 16, 2023, to February 12, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that West Pharmaceutical made false statements regarding customer demand and the impact of COVID-related product destocking, while in reality, it was experiencing significant destocking in its High-Value Products portfolio [5]. - It is alleged that West's SmartDose device, intended as a high-margin growth product, negatively impacted profit margins due to operational inefficiencies [5]. - The lawsuit indicates that these margin pressures could lead to costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [5]. - The misleading statements about West's business operations and prospects resulted in investor damages when the true situation was revealed [5]. Group 2: Participation Information - Investors who purchased West common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm for more information [3][6].

Core Viewpoint - The West Pharmaceutical Services, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934 due to misleading statements and operational inefficiencies that led to significant financial losses for investors during the specified class period [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., and it covers purchasers of West Pharmaceutical common stock from February 16, 2023, to February 12, 2025 [1]. - Investors have until July 7, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that West Pharmaceutical made false statements regarding customer demand and the performance of its high-margin products, particularly the SmartDose device [3]. Group 2: Allegations and Financial Impact - The lawsuit claims that West Pharmaceutical was experiencing significant destocking in its High-Value Products portfolio, contrary to its public statements [3]. - On February 13, 2025, West Pharmaceutical issued a revenue forecast of $2.88 billion to $2.91 billion for 2025, which was significantly below market expectations [4]. - The company attributed its disappointing guidance to the loss of two major continuous glucose monitoring (CGM) customers and operational inefficiencies related to the SmartDose device, which is expected to be margin dilutive in 2025 [4]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased West Pharmaceutical common stock during the class period to seek lead plaintiff status [5]. - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit and is recognized as a leading firm in securities fraud litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - A class action securities lawsuit has been filed against West Pharmaceutical Services, Inc. alleging securities fraud that negatively impacted investors between February 16, 2023, and February 12, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that West Pharmaceutical Services made false statements regarding customer demand visibility and attributed challenges to temporary COVID-related product destocking, while in reality, the company faced significant ongoing destocking in its high-margin HVP portfolio [3]. - It is alleged that the SmartDose device, which was marketed as a high-margin growth product, actually diluted the company's profit margins due to operational inefficiencies [3]. - The margin pressures from these issues raised the risk of costly restructuring activities, including the company's exit from continuous glucose monitoring contracts with long-standing customers [3]. - Consequently, the positive statements made by the defendants about the company's business, operations, and prospects were materially false, misleading, or lacked a reasonable basis [3]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until July 7, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [4]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

NEW YORK, May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=148835&from=4CLAS ...

West Pharmaceutical Services (WST) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked ...

Core Viewpoint - West Pharmaceutical Services (WST) has seen a 7.3% increase in share price over the past four weeks, closing at $216.64, with a potential upside of 31.1% based on Wall Street analysts' mean price target of $284 [1] Price Targets and Analyst Consensus - The average of 10 short-term price targets ranges from a low of $245 to a high of $355, with a standard deviation of $34.94, indicating variability in estimates [2] - The lowest estimate suggests a 13.1% increase, while the highest points to a 63.9% upside, highlighting the range of analyst expectations [2] - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about WST's earnings prospects, as evidenced by a trend of higher EPS estimate revisions [11] - The Zacks Consensus Estimate for the current year has risen by 1.9% over the past month, with five estimates increasing and no negative revisions [12] - WST holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13]

Core Viewpoint - West Pharmaceutical Services, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and operational inefficiencies impacting financial performance [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled New England Teamsters Pension Fund v. West Pharmaceutical Services, Inc., and covers purchasers of West Pharmaceutical common stock from February 16, 2023, to February 12, 2025 [1]. - Investors have until July 7, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that West Pharmaceutical made false statements regarding customer demand and the performance of its high-margin products [3]. Group 2: Allegations Against West Pharmaceutical - Allegations include that West Pharmaceutical was experiencing significant destocking in its High-Value Products portfolio, contrary to claims of strong visibility into customer demand [3]. - The SmartDose device, marketed as a high-margin growth product, is claimed to be dilutive to profit margins due to operational inefficiencies [3]. - The lawsuit also highlights risks of costly restructuring activities, including the exit from continuous glucose monitoring contracts with long-standing customers [3]. Group 3: Financial Impact and Stock Performance - On February 13, 2025, West Pharmaceutical issued a revenue forecast of $2.88 billion to $2.91 billion, which was significantly below market expectations [4]. - The disappointing guidance was attributed to losses of major customers transitioning to in-house manufacturing and the decision not to participate in future contracts due to unmet financial thresholds [4]. - Following the announcement, West Pharmaceutical's stock price fell by more than 38% [4].